JAK2
Tyrosine-protein kinase JAK2
As of the edition of 20 October 2026, JAK2 (tyrosine-protein kinase JAK2, UniProt O60674) has 22 drugs tested at it and 28 companies on the list, 7 on route A and 10 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- O60674
- How well studied
- Drug target: an approved drug acts on it
- Where it sits in the cell
- In more than one place
- Solved structures
- 171
- Disease areas
- Skin and connective tissue; Immune system; Blood and lymph; Cancer; Bones, joints and muscles; Lungs and airways; Digestive system; Inherited and neonatal
- Registered trials of its drugs
- 1,159
Drugs at this target
| Status | Count |
|---|---|
| Marketed | 10 |
| Active | 2 |
| Went quiet | 4 |
| Stopped | 5 |
| Status not established | 1 |
| Total | 22 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Ruxolitinib | Marketed | Phase 4 | Ends 2029 |
| Tofacitinib | Marketed | Phase 4 | Ends 2028 |
| Baricitinib | Marketed | Phase 4 | Ends 2032 |
| Upadacitinib | Marketed | Phase 4 | Ends 2036 |
| Filgotinib | Marketed | Phase 4 | none listed |
| Pacritinib | Marketed | Phase 3 | Ends 2030 |
| Peficitinib | Marketed | Phase 3 | none listed |
| Fedratinib | Marketed | Phase 3 | Ends 2031 |
| Momelotinib | Marketed | Phase 3 | Ends 2035 |
| Delgocitinib | Marketed | Phase 3 | Ends 2031 |
| TQ05105 | Active | Phase 2 | none listed |
| Gusacitinib | Stopped | Phase 2 | none listed |
12 of 22 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route A | 7 |
| Route B | 10 |
| Engaged | 6 |
| Undetermined | 5 |
| Total on the list | 28 |
The other 25 companies at JAK2
In the product28 companies in all; 25 are not named here, and no score is.
See the 28 companies at JAK2, ranked, with the facts behind eachRequest access. Nothing is shown until you do.